Lung as a target for COVID-19 : Mechanistic insights and probable candidate molecules for cure
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
Novel coronavirus (SARS nCoV2), belonging to the family coronaviridae, remains a dreadful pathogen affecting the respiratory tract and lungs. COVID-19 declared a global pandemic by WHO, has become a serious cause of concern for clinicians and researchers, who need to understand the significant biology and pathogenicity of this virus to design better treatment modalities. Existing antiretroviral drugs remain partially ineffective in critical subjects with associated co-morbidities. This review provides an insight into the molecular mechanisms by which SARS-CoV2 targets the lungs leading to ARDS in severe cases. This also addresses the possible drug targets and certain anti-inflammatory natural compounds that can be looked upon as promising adjuvant therapeutics for COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of infection and public health - 17(2024), 4 vom: 30. März, Seite 573-578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaikh, Sadiya Bi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiph.2024.01.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36857637X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36857637X | ||
| 003 | DE-627 | ||
| 005 | 20240325234859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240218s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiph.2024.01.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM36857637X | ||
| 035 | |a (NLM)38367571 | ||
| 035 | |a (PII)S1876-0341(24)00020-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shaikh, Sadiya Bi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lung as a target for COVID-19 |b Mechanistic insights and probable candidate molecules for cure |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Novel coronavirus (SARS nCoV2), belonging to the family coronaviridae, remains a dreadful pathogen affecting the respiratory tract and lungs. COVID-19 declared a global pandemic by WHO, has become a serious cause of concern for clinicians and researchers, who need to understand the significant biology and pathogenicity of this virus to design better treatment modalities. Existing antiretroviral drugs remain partially ineffective in critical subjects with associated co-morbidities. This review provides an insight into the molecular mechanisms by which SARS-CoV2 targets the lungs leading to ARDS in severe cases. This also addresses the possible drug targets and certain anti-inflammatory natural compounds that can be looked upon as promising adjuvant therapeutics for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Natural compounds | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 700 | 1 | |a Prabhu, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Akarsha B |e verfasserin |4 aut | |
| 700 | 1 | |a Rahamathulla, Mohamudha Parveen |e verfasserin |4 aut | |
| 700 | 1 | |a Sha, Mohemmed |e verfasserin |4 aut | |
| 700 | 1 | |a Bhandary, Yashodhar Prabhakar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and public health |d 2008 |g 17(2024), 4 vom: 30. März, Seite 573-578 |w (DE-627)NLM200240730 |x 1876-035X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:4 |g day:30 |g month:03 |g pages:573-578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiph.2024.01.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 4 |b 30 |c 03 |h 573-578 | ||